Adalta Ltd - Asset Resilience Ratio

Latest as of June 2024: -3.70%

Adalta Ltd (1AD) has an Asset Resilience Ratio of -3.70% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 1AD liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

AU$-206.28K

≈ $-145.96K USD Cash + Short-term Investments

Total Assets

AU$5.57 Million

≈ $3.94 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Adalta Ltd's Asset Resilience Ratio has changed over time. See Adalta Ltd (1AD) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Adalta Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adalta Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$-206.28K	-3.7%
Total Liquid Assets	AU$-206.28K	-3.70%

Asset Resilience Insights

Limited Liquidity: Adalta Ltd maintains only -3.70% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Adalta Ltd Industry Peers by Asset Resilience Ratio

Compare Adalta Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	1.39%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shanghai Shen Lian Biomedical Corp SHG:688098	Biotechnology	3.87%

Annual Asset Resilience Ratio for Adalta Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Adalta Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-06-30	-3.70%	AU$-206.28K ≈ $-145.96K	AU$5.57 Million ≈ $3.94 Million	-52.44pp
2020-06-30	48.74%	AU$3.37 Million ≈ $2.38 Million	AU$6.91 Million ≈ $4.89 Million	-10.94pp
2019-06-30	59.68%	AU$5.56 Million ≈ $3.93 Million	AU$9.31 Million ≈ $6.59 Million	+7.73pp
2018-06-30	51.95%	AU$2.31 Million ≈ $1.63 Million	AU$4.44 Million ≈ $3.14 Million	-24.99pp
2017-06-30	76.94%	AU$6.22 Million ≈ $4.40 Million	AU$8.09 Million ≈ $5.72 Million	--

pp = percentage points

About Adalta Ltd

AU:1AD Australia Biotechnology

Market Cap

$6.50 Million

AU$9.18 Million AUD

Market Cap Rank

#27838 Global

#1482 in Australia

Share Price

AU$0.00

Change (1 day)

+0.00%

52-Week Range

AU$0.00 - AU$0.01

All Time High

AU$0.37